Lasers in Glaucoma Presenter: Dr

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Lasers in Glaucoma Presenter: Dr. David Luellwitz Introducon • A laser is a device that emits light through a process of op<cal amplificaon based on the smulated emission of electromagne<c radiaon. • Proper<es of laser • Monochromac • Coherent • Parallelism • Brightness Lasers used in glaucoma 488 - 514 nm - Argon blue-green & green 810 nm Diode 1064 nm - Nd:YAG 10,600 nm - Carbon dioxide Different types of laser LASERS Gas Solid State Metal EXCIMER Dye Diode Vapour Argon Ruby Copper Argon Fluoride Krypton Nd Yag Gold Helium Neon Carbon Dioxide Three basic light-ssue interacons • Photocoagulaon • Laser light is absorbed by the target <ssue or by neighboring <ssue, generang heat that denatures proteins (i.e., coagulaon) • Photodisrup<on • Power density is so great that molecules are broken apart into their component ions, creang a rapidly expanding ion ‘plasma.’ This ionizaon and expanding plasma create subsequent shock-wave effects which cause an explosive disrup<on of <ssue to create an excision • Photoablaon: • breaks the chemical bonds that hold <ssue together, essen<ally vaporizing the <ssue Modes of operaon Con<nuous Wave (CW) Laser: It delivers the energy in a con<nuous stream of photons. Pulsed Lasers: Produce energy pulses of a few micro to milliseconds. Q Switched Lasers: Deliver energy pulses of extremely short duraon (nanosecond). Mode-locked Lasers: Emits a train of short duraon pulses (picoseconds to femtoseconds) Lasers in Open angle glaucoma • OuTlow enhancement • Laser trabeculoplasty • Inflow reduc<on • Cyclophotocoagulaon(for end stage disease) Lasers in Angle closure glaucoma • Relief of pupillary block • Laser iridotomy • Modificaon of iris contour • Laser iridoplasty • Inflow reduc<on • Cyclophotocoagulaon(end stage disease) Lasers in Post-opera3ve treatment • Laser suture lysis • Adjacent to trabeculectomy • Laser sclerostomy • Laser gonio-puncture • Adjacent to non-penetrang surgery Nd:YAG laser • Beckman and Sugar in 1973 were first to use Nd:YAG laser • Neodymium crystal is embedded in y_rium-aluminium garnet • It can be operated in • Free mode • Q-switched • Mode locked regime • Free mode has thermal effect on <ssue • While Q-switched and mode locked have photo disrup<ve effect. • Q-switched and mode locked regime • truly pulsed lasers with emissions of high power density in very short duraon. • Q-switched system • energy within the laser cavity is raised several <mes by making the usually par<ally reflec<ve mirror totally opaque. • Then suddenly making it transparent again by using polaroid filters • So there is rapid deple<on of energy confined within laser cavity. Q-switched Mode lock Duraon 10-20ns 30-70ns Irradiance 106 109 Op<cal switching Pockel cell/dye Dye Efficiency Beer Poor •In pockel cell - op<cal switching occurred by electrical modulaon •While in dye - op<cal switching occurs when the energy buildup becomes very high •So dye driven switches are inefficient and prone to malfunc<oning. Laser iridotomy • Laser treatment to connect anterior and posterior chamber to relieve pupillary block. • Effec<ve for pupillary block • Relavely non invasive • Preferable to surgical iridotomy indicaon • Definive indicaons • Acute angle closure. • Chronic (creeping) angle closure • Mixed mechanism glaucoma • Phacomorphic with an element of pupillary block • Iris bombé • Rela3ve indica3ons • Cri<cally narrow angles in asymptomac paents • Younger paents, especially those who live some distance from medical care or who travel frequently • Narrow angles with posi<ve provocave test • Iris–trabecular contact demonstrated by compression gonioscopy Types of laser • Photodisrup<ve Nd:YAG laser,(Q-switched and mode-lock) • The photothermal argon lasers Pa3ent prepara3on • Pilocarpine 1% is ins<lled twice, 5 minutes apart; miosis helps to stretch and thin the iris. • Proparacaine 0.5% drops are ins<lled immediately before the procedure Lens choice • Abraham lens- 66D planoconvex buon. • The Wise lens -103D planoconvex buon, • concentrates the laser energy more • it minimizes the spot and magnifies the target even more • difficult to focus. • Advantage of the Abraham lens -energy delivered to both cornea and re<na is four <mes less than that with Wise lens. Specific techniques • Place- peripheral iris under the upper eyelid to avoid ghost images that may arise through the iris hole. • Iris crypts represent thinner iris segments and, as such, are penetrated more easily. • The superonasal posi<on (at 11 and 1 o’clock) is the best posi<on to use to prevent inadvertent irradiaon of the fovea Laser Iridotomy - posion Nd-YAG laser • The energy- 3–8 mJ, • Pulses- there are 1–3 per shot, and one or more shots are used for penetraon • The Q-switched mode is used • Place-between the 11 and 1 o’clock posi<ons, • Iris blood vessels are avoided Argon laser • Long pulses (0.2 seconds) for light-colored irides (blue, hazel, light brown), • short pulses (0.02–0.05 seconds) for dark brown irides. • Power; 1000 mW • Spot size ; 50 μm • single area is treated with superimposed applicaons un<l perforaon is obtained • pigment flume is found to move forward (“smoke sign” or “waterfall sign”) Del Priore L.V., Robin A.L., Pollack I.P.: Neodymium:YAG and argon laser iridectomy: long term follow-up in a prospec<ve randomized clinical trial. Ophthalmology 1988; 95:1207-1211 Post laser management • Steroids are given 4 <mes a day for 7 days to reduce post laser inflammaon . • An<-glaucoma medicaon like B-blockers are given 2 <mes a day for 7 days to reduce chances of post laser IOP spike. • Paent is re-checked aer 7 days for IOP and patency of iridotomy. Argon versus Nd:YAG Laser Argon laser Nd:YAG laser • . Uptake of energy Require pigmented cells Doesn’t require Iris colour Dark brown Light and medium colour iris Late closure High chance Less chance Combined Argon Nd:YAG technique • Used in sequen<al combinaon for dark brown irides or for paents who are on chronic an<coagulant therapy • First, the argon laser (short-pulse mode) is used to aenuate the iris to about one fourth the original thickness and to coagulate vessels in the area. • Then Nd:YAG laser is used, with the beam focused at the center of the crater; one or more bursts are used to complete the iridectomy. Complica3ons • Intraocular Pressure Spikes • Laser-Induced Inflammaon • Iridectomy Failure • Diplopia • Bleeding • Lens Opaci<es • Corneal Injury Laser peripheral iridoplasty • It is an effec<ve means of opening an apposi<onally closed angle. • Procedure consists of placing contrac<on burns in the extreme periphery to contract the iris stroma between the site of burn and the angle so it physically opens an angle. • Argon laser are used with the lowest power seng that creates contrac<on of the iris Laser Iridoplasty Note the almost Ring like burns for laser iridoplasty • Spot size : 100–200- µm • Power: 100–30o mW • Duraon : 0.1 second. • Lighter irides will require slightly higher energy levels than darker • Ten to twenty spots evenly distributed over 360º of the iris are usually sufficient Indicaon • A_ack of angle closure glaucoma • Plateau iris syndrome commonest indicaon • Angle closure related to size or posi<on of lens • Nanophthalmos • Facilitate access to the trabecular meshwork for laser trabeculoplasty • Minimize the risk of endothelial damage during iridotomy Contraindica3ons • Contraindicaon • Advanced corneal edema or opacificaon • Flat anterior chamber • Synechial angle closure • Complicaon: • mild iris • Corneal endothelial burn • Transient rise in IOP Laser trabeculoplasty • Relavely effecve,non-invasive. • Laser treatment to trabecular meshwork increase to increase oulow. Mechanism of ac3on • Wise and Wi_er proposed that thermal energy produced by absorp<on of laser by pigmented trabecular meshwork caused shrinkage of collagen of trabecular lamellae this opened up intertrabecular space in untreated region and expanded schlemm’s canal by pulling the meshwork centrally • Eliminaon of some trabecular cells pos_rbeculoplasty.this s<mulate remaining cells to produce different composi<on of extracellular matrix with lesser ouTlow obstruc<ng proper<es. Laser trabeculoplasty • Method • Argon laser trabeculoplasty • Selec<ve laser trabeculoplasty • Lens • Goldmann 3 mirror lens • Lana trabeculoplasty lens: Argon laser trabeculoplasty • Laser parameter • Power -300-1200mW • Spot size—50µm • Duraon -0.1 sec • Number of burns-30-50 spots evenly placed over 180deg. remaining in subsequent visit. Argon laser trabeculoplasty • Ideally,spot should be applied Over schlemm’s canal avoding The iris root at the junc<on of Anterior 1/3 to posterior 2/3 of Meshwork. • The energy level should be set To induce a reac<on from a Slight transient blanching of The treated area to small Bubble formaon Selecve laser trabeculoplasty • SLT target pigmented trabecular meshwork cells without causing thermal damage to non-pigmented cells or structure. • Laser :Frequency doubled Q switched ND:YAG laser • Pulse :3nsec. • Spot size 400 µm • Power :o.8 mJ power • No.of spots :apprx.50 spots are applied • End point :minimal bubble or no bubble Selecve laser trabeculoplasty (arrow) versus argon laser trabeculoplasty treatment (arrowhead). (Courtesy of M. Berlin, MD.) Comparison ALT SLT TYPE OF LASER Argon blue green 488/514nm Double frequency Nd:YAG 532nm Spot size(µm) 50 400 Duraon 0.1s 3ns Power 300–900 mW 0.6–1.2 mJ Degrees 180 180–360 Indicaons • Chronic open angle glaucoma • Exfoliaon syndrome • Pigmentary glaucoma • Glaucoma in aphakia or pseudophakia Contraindica3ons • Closed or extremely narrow angles • Corneal
Recommended publications
  • Short-Term Changes in the Photopic Negative Response Following Intraocular Pressure Lowering in Glaucoma

    Short-Term Changes in the Photopic Negative Response Following Intraocular Pressure Lowering in Glaucoma

    Glaucoma Short-Term Changes in the Photopic Negative Response Following Intraocular Pressure Lowering in Glaucoma Jessica Tang,1,2 Flora Hui,1 Xavier Hadoux,1 Bernardo Soares,3 Michael Jamieson,3 Peter van Wijngaarden,1–3 Michael Coote,1–3 and Jonathan G. Crowston1,2,4,5 1Glaucoma Research Unit, Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia 2Ophthalmology, Department of Surgery, The University of Melbourne, Melbourne, Australia 3Royal Victorian Eye and Ear Hospital, Melbourne, Australia 4Centre for Vision Research, Duke-NUS Medical School, Singapore, Singapore 5Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore Correspondence: Jessica Tang, PURPOSE. To evaluate the short-term changes in inner retinal function using the photopic Glaucoma Research Unit, Centre for negative response (PhNR) after intraocular pressure (IOP) reduction in glaucoma. Eye Research Australia, Royal Victorian Eye and Ear Hospital, METHODS. Forty-seven participants with glaucoma who were commencing a new or addi- Level 7, Peter Howson Wing, 32 tional IOP-lowering therapy (treatment group) and 39 participants with stable glau- Gisborne St, East Melbourne, VIC coma (control group) were recruited. IOP, visual field, retinal nerve fiber layer thick- 3002, Australia; ness, and electroretinograms (ERGs) were recorded at baseline and at a follow-up visit [email protected]. (3 ± 2 months). An optimized protocol developed for a portable ERG device was used Received: August 29, 2019 to record the PhNR. The PhNR saturated amplitude (Vmax), Vmax ratio, semi-saturation Accepted: June 16, 2020 constant (K), and slope of the Naka–Rushton function were analyzed. Published: August 7, 2020 RESULTS.
  • Laser Learning Lecture and Lab: YAG Caps, LPI, And

    Laser Learning Lecture and Lab: YAG Caps, LPI, And

    5/9/17 Overview Laser Learning Lecture and Lab: • Why we use lasers YAG caps, LPI, and SLT • YAG capsulotomy • Laser Peripheral Iridotomy (LPI or PI) Aaron McNulty, O.D., F.A.A.O. • Argon Laser Peripheral Iridoplasty (ALPI) Nate Lighthizer, O.D., F.A.A.O. • Argon Laser Trabeculoplasty (ALT) • Selective Laser Trabeculoplasty (SLT) • Other Laser Trabeculoplasty Why do we use lasers? Posterior Capsular Opacification (PCO) • Vision is decreased from PCO following cataract surgery • Lens capsular bag has an anterior and • Narrow angles/angle closure posterior surface • Glaucoma is progressing in a pt on max meds – Anterior surface usually removed w/ capsulorhexis – Something else needs to be done – Surgery not wanted yet • PCO is the formation of a cloudy membrane • Compliance issues on the posterior surface of the capsular bag • Cost issues following ECCE • Convenience issues – AKA: Secondary cataract • Doctor preference PCO YAG Laser • Incidence: • Nd: YAG laser – Most common complication of post ECCE – Neodymium: Yttrium aluminum garnet laser – 10-80% of eyes following cataract surgery – Can form anywhere from a few days to years post surgery • Tissue interaction: Photodisruptive laser – Younger patients higher risk of PCO – High light energy levels cause the tissues to be reduced – IOL’s to plasma, disintegrating the tissue • Silicone > acrylic – A large amount of energy is delivered into very small focal spots in a very brief duration of time • Prevention: • 4 nsec – – Capsulotomy during surgery No thermal reaction/No coagulation when bv’s are hit – Posterior capsular polishing – Pigment independent* 1 5/9/17 YAG Cap Risks, Complications, YAG Cap Pre-op Exam Contraindications • Visual acuity, glare testing, PAM/Heine lambda Contraindications Risks/complications – Vision 20/30 or worse 1.
  • Laser Procedures for the Management of Glaucoma and More Handout

    Laser Procedures for the Management of Glaucoma and More Handout

    4/25/17 Overview Laser Procedures for the Management • Why we use lasers of Glaucoma and More • YAG capsulotomy Nate Lighthizer, O.D., F.A.A.O. • Laser Peripheral Iridotomy (LPI or PI) Assistant Professor, NSUOCO • Argon Laser Peripheral Iridoplasty (ALPI) Assistant Dean, Clinical Care Services • Argon Laser Trabeculoplasty (ALT) Director of CE Chief of Specialty Care Clinics • Selective Laser Trabeculoplasty (SLT) Chief of Electrodiagnostics Clinic • Other Laser Trabeculoplasty [email protected] Why do we use lasers? Posterior Capsular Opacification (PCO) • Vision is decreased from PCO following cataract surgery • Lens capsular bag has an anterior and • Narrow angles/angle closure posterior surface • Glaucoma is progressing in a pt on max meds – Anterior surface usually removed w/ capsulorhexis – Something else needs to be done – Surgery not wanted yet • PCO is the formation of a cloudy membrane • Compliance issues on the posterior surface of the capsular bag • Cost issues following ECCE • Convenience issues – AKA: Secondary cataract • Doctor preference PCO YAG Laser • Incidence: • Nd: YAG laser – Most common complication of post ECCE – Neodymium: Yttrium aluminum garnet laser – 10-80% of eyes following cataract surgery – Can form anywhere from a few days to years post surgery • Tissue interaction: Photodisruptive laser – Younger patients higher risk of PCO – High light energy levels cause the tissues to be reduced – IOL’s to plasma, disintegrating the tissue • Silicone > acrylic – A large amount of energy is delivered into very small focal spots in a very brief duration of time • Prevention: • 4 nsec – – Capsulotomy during surgery No thermal reaction/No coagulation when bv’s are hit – Posterior capsular polishing – Pigment independent* 1 4/25/17 YAG Cap Risks, Complications, YAG Cap Pre-op Exam Contraindications • Visual acuity, glare testing, PAM/Heine lambda Contraindications Risks/complications – Vision 20/30 or worse 1.
  • Main Types of Lasers Used for Manufacturing- Key Properties and Key Applications

    Main Types of Lasers Used for Manufacturing- Key Properties and Key Applications

    Main Types of Lasers Used for Manufacturing- Key Properties and Key Applications Tom Kugler Fiber Systems Mgr. Laser Mechanisms, Inc. www.lasermech.com LME 2011 Topics • Laser Output Wavelengths • Laser Average Power • Laser Output Waveforms (Pulsing) • Laser Peak Power • Laser Beam Quality (Focusability) • Key Properties • Key Applications • Beam Delivery Styles 2 Tom Kugler- Laser Mechanisms Compared to standard light sources… • Laser Light is Collimated- the light rays are parallel to and diverge very slowly- they stay concentrated over long distances- that is a “laser beam” • Laser Light has high Power Density- parallel laser light has a power density in watts/cm2 that is over 1000 times that of ordinary incandescent light • Laser Light is Monochromatic- one color (wavelength) so optics are simplified and perform better • Laser light is highly Focusable- low divergence, small diameter beams, and monochromatic light mean the laser can be focused to a small focal point producing power densities at focus 1,000,000,000 times more than ordinary light. 3 Tom Kugler- Laser Mechanisms Laser Light • 100W of laser light focused to a diameter of 100um produces a power density of 1,270,000 Watts per square centimeter! 4 Tom Kugler- Laser Mechanisms Examples of Laser Types • Gas Lasers: Electrical Discharge in a Gas Mixture Excites Laser Action: – Carbon Dioxide (CO2) – Excimer (XeCl, KrF, ArF, XeF) • Light Pumped Solid State Lasers: Light from Lamps or Diodes Excites Ions in a Host Crystal or Glass: – Nd:YAG (Neodymium doped Yttrium Aluminum
  • Bjophthalmol-2020-318090 1..2

    Bjophthalmol-2020-318090 1..2

    At a glance Br J Ophthalmol: first published as 10.1136/bjophthalmol-2020-318090 on 26 October 2020. Downloaded from Highlights from this issue doi:10.1136/bjophthalmol-2020-318090 Keith Barton , James Chodosh , Jost B Jonas , Editors in chief Glaucoma in the Northern Ireland Cohort The effect of partial posterior vitreous Comparison of OCT angiography in for the Longitudinal Study of Ageing detachment on spectral-domain optical children with a history of intravitreal (NICOLA): cohort profile, prevalence, coherence tomography retinal nerve fibre injection of ranibizumab vs laser awareness and associations (seepage1492) layer thickness measurements photocoagulation for retinopathy of The crude prevalence of glaucoma in (seepage1524) prematurity (see page 1556) Northern Ireland of 2.83% (95% CI Among glaucoma suspects, eyes with par- In this cross-sectional study, we found that 2.31%, 3.46%) is comparable to other tial posterior vitreous detachments, com- the central foveal vessel length density and European population-based studies. pared to eyes without, were associated perfusion density, the foveal avascular Approximately two thirds of people with with greater average, superior, and inferior zone area and central foveal thicknesses glaucoma were undiagnosed. Associations retinal nerve fibre layer thickness of children who had undergone different with glaucoma were consistent with cur- measurements. treatments, might vary. rent understanding of the disease. Three-year follow-up of choroidal Comparison of central visual sensitivity Selective
  • A Review of Selective Laser Trabeculoplasty: Recent Findings and Current Perspectives

    A Review of Selective Laser Trabeculoplasty: Recent Findings and Current Perspectives

    Ophthalmol Ther DOI 10.1007/s40123-017-0082-x REVIEW A Review of Selective Laser Trabeculoplasty: Recent Findings and Current Perspectives Yujia Zhou . Ahmad A. Aref Received: January 17, 2017 Ó The Author(s) 2017. This article is published with open access at Springerlink.com ABSTRACT explored, revealing that minor modifications may lead to a more favorable or safer clinical Selective laser trabeculoplasty (SLT) has been outcome. The utilization of postoperative widely used in the clinical management of medications remains controversial based on the glaucoma, both as primary and adjunctive current evidence. A short-term IOP increase treatment. As new evidence continues to arise, may complicate SLT and can also persist in we review the current literature in terms of certain cases such as in exfoliation glaucoma. indications and efficacy, surgical technique, The efficacy and safety of repeat SLT are shown postoperative care, repeatability, and compli- in multiple studies, and the timing of repeat cations of this therapy. SLT has been shown to procedures may affect the success rate. be effective in various glaucomas, including primary open-angle glaucoma (POAG), nor- mal-tension glaucoma (NTG), steroid-induced Keywords: Glaucoma; Intraocular pressure; glaucoma, pseudoexfoliation glaucoma (PXFG), Laser; Selective laser trabeculoplasty and primary angle-closure glaucoma (PACG), as well as other glaucoma subtypes. Relatively high preoperative intraocular pressure (IOP) INTRODUCTION may predict surgical success, while other parameters that have been studied do not seem Intraocular pressure (IOP) reduction is the to affect the outcome. Different techniques for mainstay of therapy for glaucomatous optic performing the procedure have recently been neuropathy. Selective laser trabeculoplasty (SLT) has been widely employed for this pur- Enhanced content To view enhanced content for this pose over the past several years as both a pri- article go to http://www.medengine.com/Redeem/ mary and adjunctive treatment [1].
  • Laser Trabeculoplasty for Open-Angle Glaucoma a Report by the American Academy of Ophthalmology

    Laser Trabeculoplasty for Open-Angle Glaucoma a Report by the American Academy of Ophthalmology

    Laser Trabeculoplasty for Open-Angle Glaucoma A Report by the American Academy of Ophthalmology John R. Samples, MD,1 Kuldev Singh, MD, MPH,2 Shan C. Lin, MD,3 Brian A. Francis, MD,4 Elizabeth Hodapp, MD,5 Henry D. Jampel, MD, MHS,6 Scott D. Smith, MD, MPH7 Objective: To provide an evidence-based summary of the outcomes, repeatability, and safety of laser trabeculoplasty for open-angle glaucoma. Methods: A search of the peer-reviewed literature in the PubMed and the Cochrane Library databases was conducted in June 2008 and was last repeated in March 2010 with no date or language restrictions. The search yielded 637 unique citations, of which 145 were considered to be of possible clinical relevance for further review and were included in the evidence analysis. Results: Level I evidence indicates an acceptable long-term efficacy of initial argon laser trabeculoplasty for open-angle glaucoma compared with initial medical treatment. Among the remaining studies, level II evidence supports the efficacy of selective laser trabeculoplasty for lowering intraocular pressure for patients with open-angle glaucoma. Level III evidence supports the efficacy of repeat use of laser trabeculoplasty. Conclusions: Laser trabeculoplasty is successful in lowering intraocular pressure for patients with open- angle glaucoma. At this time, there is no literature establishing the superiority of any particular form of laser trabeculoplasty. The theories of action of laser trabeculoplasty are not elucidated fully. Further research into the differences among the lasers used in trabeculoplasty, the repeatability of the procedure, and techniques of treatment is necessary. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.
  • Objective Assessment of Retinal Ganglion Cell Function in Glaucoma

    Objective Assessment of Retinal Ganglion Cell Function in Glaucoma

    Objective Assessment of Retinal Ganglion Cell Function in Glaucoma Submitted by Nabin R. Joshi DISSERTATION In partial satisfaction of the requirements for the degree of Doctor of Philosophy SUNY College of Optometry (September 25th, 2017) 1 Abstract Background Glaucoma refers to a group of diseases causing progressive degeneration of the retinal ganglion cells. It is a clinical diagnosis based on the evidence of structural damage of the optic nerve head with corresponding visual field loss. Structural damage is assessed by visualization of the optic nerve head (ONH) through various imaging and observational techniques, while the behavioral loss of sensitivity is assessed with an automated perimeter. However, given the subjective nature of visual field assessment in patients, visual function examination suffers from high variability as well as patient and operator- related biases. To overcome these drawbacks, past research has focused on the use of objective methods of quantifying retinal function in patients with glaucoma such as electroretinograms, visually evoked potentials, pupillometry etc. Electroretinograms are objective, non-invasive method of assessing retinal function, and careful manipulation of the visual input or stimulus can result in extraction of signals particular to select classes of the retinal cells, and photopic negative response (PhNR) is a component of ERG that reflects primarily the retinal ganglion cell function. On the other hand, pupillary response to light, measured objectively with a pupillometer, also indicates the functional state of the retina and the pupillary pathway. Hence, the study of both ERGs and pupillary response to light provide an objective avenue of research towards understanding the mechanisms of neurodegeneration in glaucoma, possibly affecting the clinical care of the patients in the long run.
  • Glaucoma Comanagement: Surgical

    Glaucoma Comanagement: Surgical

    6/27/2017 Virginia Eye Consultants Tertiary Referral Eye Care Since 1963 • John D. Sheppard, MD, MMSc • Walter O. Whitley, OD, MBA, FAAO Innovations in Glaucoma • Stephen V. Scoper, MD • Mark Enochs, OD • David Salib, MD • Cecelia Koetting, OD, FAAO COPE#52116-GL • Elizabeth Yeu, MD • Christopher Kuc, OD • Thomas J. Joly, MD, PhD • Leanna Olennikov, OD • Dayna M. Lago, MD • Jillian Janes, OD • Constance Okeke, MD, MSCE Walter O. Whitley, OD, MBA, FAAO • Esther Chang, MD Director of Optometric Services • Jay Starling, MD Virginia Eye Consultants • Samantha Dewundara, MD Residency Program Supervisor • Surajit Saha, MD Pennsylvania College of Optometry Disclosures Walter O. Whitley, OD, MBA, FAAO has received consulting fees, honorarium or research funding from: • Alcon • Diopsys • Allergan • Ocusoft • Bausch and Lomb • Science Based Health • Biotissue • Shire • Beaver-Visitec • TearLab Corporation • Publications – Advanced Ocular Care – Co-Chief Medical Editor – Review of Optometry – Contributing Editor – Optometry Times – Editorial Advisory Board The Most Valuable Glaucoma Tool Glaucoma: Diagnosis • We know it when we see it IOP: 26 OU 1 6/27/2017 Glaucoma Diagnosis Glaucoma Diagnosis • Gonioscopy • Central corneal thickness • Visual fields • Fundus photography • Scanning lasers • Serial tonometry • Electrodiagnositics – VEP / PERG GLAUCOMA SEVERITY SCALE Managing Glaucoma Patients DEFINITIONS • Mild Stage: optic nerve changes consistent with glaucoma but • Monitor IOP reduction: 1-2 week, 1 month NO visual field abnormalities on any visual field test OR abnormalities present only on short-wavelength automated • Check IOP every 3-4 months perimetry or frequency doubling perimetry. • Repeat VF every 6-12 months • Moderate Stage: optic nerve changes consistent with • Disc photos every 1-2 years glaucoma AND glaucomatous visual field abnormalities in one hemifield and not within 5 degrees of fixation.
  • Detection of Lead in Soil with Excimer Laser Fragmentation Fluorescence Spectroscopy (ELFFS)

    Detection of Lead in Soil with Excimer Laser Fragmentation Fluorescence Spectroscopy (ELFFS)

    Detection of Lead in Soil with Excimer Laser Fragmentation Fluorescence Spectroscopy (ELFFS) J. H. Choi1, C. J. Damm2, N. J. O’Donovan1, R. F. Sawyer1, C. P. Koshland2, and D. Lucas3† 1Mechanical Engineering Department, University of California, Berkeley, CA 94720 2Science & Technology Department, Sierra Nevada College, NV 89451 3School of Public Health, University of California, Berkeley, CA 94720 4Environmental Energy Technologies Division, Lawrence Berkeley National Laboratory Berkeley, CA 94720 Date: 2/2/04 † Corresponding Author [email protected] PH: (510) 486-7002 FAX: (510) 486-7303 Index Headings: Photofragmentation; Fluorescence; Photochemistry; Plasma; Lead. 1 ABSTRACT Excimer laser fragmentation fluorescence spectroscopy (ELFFS) is used to monitor lead in soil sample and investigate laser-solid interactions. Pure lead nitrate salt and soil doped with lead nitrate are photolyzed with 193 nm light from an ArF excimer at fluences from 0.4 to 4 J/cm2. Lead emission is observed at 357.2, 364.0, 368.3, 373.9 and 405.8 nm. Time-resolved data show the decay time of the lead emission at 405.8 nm grows with increasing fluence, and a plasma is formed above fluences of 2 J/cm2, where a strong continuum emission interferes with the analyte signal. Fluences below this threshold allow us to achieve a detection limit of approximately 200 ppm in soil. INTRODUCTION Lead (Pb) poisoning from environmental and occupational exposure remains one of the most common and preventable diseases. There are numerous serious and detrimental health effects from inhalation or ingestion of lead, including poisoning or even death in extreme circumstances1. Various in situ, real-time methods to measure heavy metals in soil have been developed as a replacement for conventional wet-chemistry techniques that require laborious and time consuming processes, such as preparation, dissolution, chelation, and ion exchange2,3.
  • Refractive Management/Intervention 2017-2019

    Refractive Management/Intervention 2017-2019

    Academy MOC Essentials® Practicing Ophthalmologists Curriculum 2017–2019 Refractive Management/Intervention *** Refractive Management/Intervention 2 © AAO 2017-2019 Practicing Ophthalmologists Curriculum Disclaimer and Limitation of Liability As a service to its members and American Board of Ophthalmology (ABO) diplomates, the American Academy of Ophthalmology has developed the Practicing Ophthalmologists Curriculum (POC) as a tool for members to prepare for the Maintenance of Certification (MOC) -related examinations. The Academy provides this material for educational purposes only. The POC should not be deemed inclusive of all proper methods of care or exclusive of other methods of care reasonably directed at obtaining the best results. The physician must make the ultimate judgment about the propriety of the care of a particular patient in light of all the circumstances presented by that patient. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise out of the use of any information contained herein. References to certain drugs, instruments, and other products in the POC are made for illustrative purposes only and are not intended to constitute an endorsement of such. Such material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law.
  • D'évaluation Des Technologies De La Santé Du Québec

    D'évaluation Des Technologies De La Santé Du Québec

    (CETS 2000-2 RE) Report – June 2000 A STATE-OF-KNOWLEDGE UPDATE THE EXCIMER LASER IN OPHTHALMOLOGY: Conseil d’Évaluation des Technologies de la Santé du Québec Report submitted to the Minister of Research, Science And Technology of Québec Conseil d’évaluation des technologies de la santé du Québec Information concerning this report or any other report published by the Conseil d'évaluation des tech- nologies de la santé can be obtained by contacting AÉTMIS. On June 28, 2000 was created the Agence d’évaluation des technologies et des modes d’intervention en santé (AÉTMIS) which took over from the Conseil d’évaluation des technologies de la santé. Agence d’évaluation des technologies et des modes d’intervention en santé 2021, avenue Union, Bureau 1040 Montréal (Québec) H3A 2S9 Telephone: (514) 873-2563 Fax: (514) 873-1369 E-mail: [email protected] Web site address: http://www.aetmis.gouv.qc.ca Legal deposit - Bibliothèque nationale du Québec, 2001 - National Library of Canada ISBN 2-550-37028-7 How to cite this report : Conseil d’évaluation des technologies de la santé du Québec. The excimer laser in ophtalmology: A state- of-knowledge update (CÉTS 2000-2 RE). Montréal: CÉTS, 2000, xi- 103 p Conseil d’évaluation des technologies de la santé du Québec THE EXCIMER LASER IN OPHTHALMOLOGY: A MANDATE STATE-OF-KNOWLEDGE UPDATE To promote and support health technology assessment, In May 1997, the Conseil d’évaluation des technologies de disseminate the results of the assessments and la santé du Québec (CETS) published a report dealing spe- encourage their use in decision making by all cifically with excimer laser photorefractive keratectomy stakeholders involved in the diffusion of these (PRK).